Kymera eczema trial readout raises stakes for Dupixent rivals
Investors and physicians are waiting for mid-stage Kymera eczema data as the company seeks a place in a market long dominated by Dupixent.
Cutaneous medicine, inflammatory skin diseases and clinical dermatology.
Cutaneous medicine, inflammatory skin diseases and clinical dermatology.